Abstract
Midgut carcinoid tumours are uncommon tumours with an unpredictable clinical behaviour and few useful prognostic markers. Somatostatin analogues are widely used in treatment but a survival advantage has not been proven. We analysed features associated with poor prognosis and assessed the clinical implications of the biochemical response to therapy.
Original language | English |
---|---|
Pages (from-to) | 1586-91 |
Number of pages | 6 |
Journal | Gut |
Volume | 55 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2006 |
ASJC Scopus subject areas
- Gastroenterology